CAPN2

Across TCGA pan-cancer cohorts, CAPN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CAPN2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CAPN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAPN2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where CAPN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.517	0.912	.003	39	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
CCRCC	OS	Quartile	II,III,IV	0.577	0.913	.018	8	view →
COAD	DFS	Median	III,IV	1.000	0.843	.042	6	view →
UCEC	DFS	Median	III,IV	0.445	0.904	.037	4	view →
HNSC	DFS	Tertile	II,III,IV	0.512	0.733	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CAPN2–LSCC (DFS)

Open the LSCC breakdown →